13th May 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Roche Pharma introduces PHESGO for the treatment of HER-2 positive breast cancer

Roche Pharma has announced the launch of PHESGO in India, the first fixed dose formulation in oncology to combine two monoclonal antibodies for the treatment of HER2-positive breast cancer, both early and metastatic.

Philips develops its manufacturing and R&D capabilities in India

Royal Philips has announced the establishment of a new R&D (Research and Development) centre in Pune to increase innovative capabilities and further invest in India.

Prime Minister Modi seeks to streamline WHO's vaccine approval procedure

PM Narendra Modi stated that the WHO must be overhauled in order to construct a more resilient global health security architecture, particularly by streamlining its vaccination and medicinal approval processes.

Sun Pharma received FDA approval for its generic medicine Mesalamine

The pharmaceutical company has gained final approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Mesalamine extended release capsules, 500 mg.

No reason to fear over reports of Tomato Flu in Kerala

Karnataka state is currently under the grip of tomato flu. The condition, which gets its name from the tomato-like blisters it generates, is an uncommon viral flu that causes red-colored rashes, skin irritation, and dehydration.

Moderna completed its FDA proposal for the use of COVID shots in adolescents & children

Moderna has completed all requisite filings to the US Food and Drug Administration for emergency use permission of its COVID-19 vaccination in adolescents and children.

AstraZeneca's metastatic breast cancer treatment approved by the FDA

Enhertu has been approved by the FDA for patients with HER2-positive metastatic breast cancer who have previously been treated with an anti-HER2-based regimen.

FDA approved Lilly-Covid-19 Incyte's therapy

The US Food and Drug Administration (FDA) has approved Eli Lilly and Company and Incyte’s Olumiant (baricitinib) to treat Covid-19 in adult hospitalised patients.